AOD-9604 5mg Research Peptide: A Complete Laboratory Guide

November 19, 2026
AOD-9604 5mg laboratory guide banner with the Ascend Peptides UK AOD-9604 5mg vial

⚠️ Research Use Only. AOD-9604 5mg is supplied strictly for in-vitro laboratory research. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All information below reflects peer-reviewed preclinical and scientific literature only. This content is not medical advice. Ascend Peptides UK accepts no liability for misuse of this product

AOD-9604 is a research peptide that has attracted significant scientific interest across the metabolic biology and adipose tissue research communities. Derived from a specific fragment of human Growth Hormone, it presents a focused tool for laboratory investigations into lipid metabolism, adipocyte biology, and cellular energy regulation without the full growth-promoting activity of the complete GH molecule.

This guide is written for both laboratory scientists and research professionals who need a thorough scientific reference, and for scientifically curious individuals who want to understand the biochemistry behind this compound and why it continues to generate active research interest. It separates published findings from open questions and is framed in the context of controlled laboratory investigation.

Ascend Peptides UK supplies AOD-9604 5mg as a research peptide for laboratory investigation only. All content in this guide is provided strictly for scientific and educational purposes. This compound is not intended for human consumption, clinical application, or therapeutic use under any circumstances.

The Scientific Foundation: Human Growth Hormone and the GH C-Terminal Fragment

To understand AOD-9604 and its significance as a research compound, it is essential to first understand its origin: the human Growth Hormone molecule and the biological significance of its C-terminal region.

Human Growth Hormone (hGH) is a 191-amino acid peptide hormone produced and secreted by somatotroph cells of the anterior pituitary gland. It is one of the most pleiotropic hormones in human biology, regulating a wide range of physiological processes, including cell growth and proliferation, protein synthesis, carbohydrate and lipid metabolism, and body composition.

The biological actions of GH are mediated through multiple mechanisms. Its anabolic and growth-promoting effects are largely indirect, primarily via stimulation of hepatic IGF-1 production, whilst its direct metabolic effects, particularly those related to lipid metabolism and adipose tissue regulation, are believed to be mediated by specific domains within the GH molecule itself.

Early research into the structure-function relationships of the GH molecule identified the C-terminal region, specifically residues 176–191 as a domain with particular relevance to metabolic activity in laboratory models. This region was found to exhibit lipolytic properties in adipose tissue research without the insulin-antagonistic and growth-promoting effects associated with the full GH molecule. This discovery formed the scientific basis for the development of AOD-9604 as a focused research tool for metabolic biology investigation.

What Is AOD-9604? Structure, Derivation, and Research Rationale

AOD-9604 is a synthetic peptide consisting of residues 177–191 of the human Growth Hormone sequence with an added tyrosine (Tyr) residue at the N-terminus, described in the literature as Tyr-hGH(177-191). The ‘AOD’ designation stands for ‘Anti-Obesity Drug’, reflecting the original research focus of the compound’s development. The number 9604 is a laboratory identifier assigned during its development at Monash University in Australia.

The complete sequence of this research compound is: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a disulphide bond between the two cysteine residues (Cys-7 and Cys-14) that closes the peptide into a loop.

The added N-terminal tyrosine distinguishes AOD-9604 from the unmodified hGH sequence. The disulphide bond closes the peptide into a loop. No specific receptor for AOD-9604 has been identified.

AOD-9604 vs Full-Length Growth Hormone: Why the Fragment Matters

Understanding the distinction between AOD-9604 and full-length human Growth Hormone is fundamental to appreciating its value as a focused research tool. The key differences that make this fragment scientifically interesting are:

  • Absence of IGF-1 stimulation: Unlike full-length GH, this compound did not change serum IGF-1 in placebo-controlled human trials (Stier et al., 2013), an important distinction for researchers wishing to study metabolic GH-related pathways without the confounding variable of IGF-1 pathway activation. For comparison, our IGF-1 LR3 research provides insight into how IGF-1 signalling is studied as a separate downstream variable.

  • Selective metabolic activity: Research has documented that the C-terminal GH fragment exhibits activity in lipid metabolism pathways in laboratory models, particularly lipolysis in adipose tissue from obese rodents (Ng et al., 2000; Heffernan et al., 2001), without the full growth-promoting and insulin-antagonistic effects of the complete GH molecule.

  • Receptor specificity: No specific receptor for AOD-9604 has been identified. In mice, its lipolytic actions were reported not to be mediated directly through the β3-adrenergic receptor (Heffernan et al., 2001).

  • Structural focus: As a 16-amino acid peptide, this research compound is much smaller than the 191-amino acid full GH molecule.

Mechanism of Action in Laboratory Research Models

The precise mechanism by which AOD-9604 exerts its effects in laboratory research models is an area of active scientific investigation. Published research has proposed and examined several potential mechanisms:

Beta-3 Adrenergic Receptor Research

A substantial body of published research has examined the relationship between this GH fragment and beta-3 adrenergic receptors (β3-AR) in adipose tissue research models. The β3-AR is expressed predominantly in adipose tissue and plays an important role in regulating lipolysis the breakdown of stored triglycerides into free fatty acids and glycerol. In obese mice, treatment increased β3-AR mRNA levels, but in β3-AR knock-out mice chronic treatment did not produce the weight loss or increased lipolysis seen in wild-type animals. The authors concluded that its lipolytic actions are not mediated directly through the β3-AR (Heffernan et al., Endocrinology, 2001); the precise mechanism has not been established.

Lipolysis in Obese Rodent Models

In obese Zucker rats given AOD-9604 orally for 19 days, adipose tissue showed increased lipolytic activity, weight gain was reduced, and euglycaemic clamp studies showed no adverse effect on insulin sensitivity (Ng et al., 2000). Effects on specific lipolytic enzymes, such as hormone-sensitive lipase or lipoprotein lipase, were not reported in the sources reviewed for this guide.

Lipogenesis and Adipogenesis: What Is and Is Not Established

Reduced lipogenesis was reported in obese mice and in rodent and human adipose tissue for AOD9401, the closely related fragment hGH 177-191 without the added tyrosine (Heffernan et al., 2000). That finding should not be assumed for AOD-9604 itself. Published AOD-9604 data on adipogenesis (pre-adipocyte differentiation) or on transcription factors such as PPARγ and C/EBPα were not found in the sources reviewed for this guide.

Cartilage Research

One animal study has examined cartilage. In a collagenase-induced knee osteoarthritis model in rabbits, intra-articular AOD-9604, alone or with hyaluronic acid, was associated with lower cartilage-degeneration scores than saline (Ann Clin Lab Sci, 2015). This is a single animal study; chondrocyte cell-model data and bone data were not found in the sources reviewed for this guide.

Relationship to the GH-IGF-1 Axis

Because this fragment did not change serum IGF-1 in placebo-controlled human trials (Stier et al., 2013), it provides researchers with a tool to study the IGF-1-independent aspects of GH signalling in metabolic biology. This makes it a complementary research compound to IGF-1 receptor studies. For laboratories investigating the downstream growth factor signalling pathway separately, our IGF-1 LR3 research guide provides detailed information on how IGF-1 LR3 is used to study growth factor receptor biology in controlled research settings.
AOD-9604 mechanism of action, GH fragment, adipose tissue lipolysis research diagram

Research Applications of AOD-9604 5mg in Laboratory Settings

The scientific literature documents a range of laboratory research contexts in which AOD-9604 5mg has been applied. The following summarises the primary research disciplines:

1. Adipose Tissue and Lipid Metabolism Research

The most published research area for this GH fragment is adipose tissue biology and lipid metabolism, mainly in obese rodent models (Ng et al., 2000; Heffernan et al., 2001). In-vitro adipocyte models can be used to examine lipolytic signalling, but the published in-vitro evidence specific to AOD-9604 is limited.

2. Adipogenesis and Pre-Adipocyte Differentiation Research

Pre-adipocyte differentiation (adipogenesis) is a possible research application, but published AOD-9604 data in differentiation models were not found in the sources reviewed for this guide, so work in this area would be exploratory.

3. Beta-3 Adrenergic Receptor Expression Research

Heffernan et al. (2001) reported that AOD-9604 restored β3-AR mRNA in adipose tissue of obese mice towards lean levels, while showing that its lipolytic effect does not depend directly on the β3-AR. β3-AR expression is therefore a documented but indirect readout.

4. Metabolic Regulation and Energy Homeostasis Research

In β3-AR knock-out mice, a single dose of AOD-9604 still increased energy expenditure and fat oxidation (Heffernan et al., 2001). Broader energy-metabolism questions, such as mitochondrial function in adipocytes, have not been established for AOD-9604 in the sources reviewed for this guide.

5. Cartilage and Musculoskeletal Biology Research

Cartilage research is currently limited to the single rabbit osteoarthritis study described in the mechanism section (Ann Clin Lab Sci, 2015).

6. Comparative GH Signalling Research

Research programmes studying the relative contributions of different GH signalling domains, growth-promoting vs. metabolic use this compound in comparison with full-length GH, other GH fragments, and related research tools. For laboratories studying the broader GH-related research peptide landscape, this compound complements GHRH analogue research. Our CJC-1295 Without DAC research guide covers GHRH receptor activation as the upstream stimulus for GH secretion, providing important context for understanding where AOD-9604 sits within the broader GH signalling research framework.

7. Multi-Pathway Research Programmes

Some research programmes investigate multiple peptides operating across complementary biological pathways simultaneously. For researchers studying metabolic and cellular biology research peptides alongside this compound, our BPC-157 10mg research guide provides a comprehensive overview of how that pentadecapeptide is applied in connective tissue and cellular signalling research a complementary area of laboratory investigation.

AOD-9604 5mg vs 10mg: Choosing the Right Format for Your Research

AOD-9604 is available from Ascend Peptides UK in both 5mg and 10mg formats. Selecting the appropriate quantity depends on the scale and stage of the research programme:

  • AOD-9604 5mg is ideal for smaller-scale laboratory work, pilot studies, method development, and research programmes that are incorporating this compound for the first time. The 5mg quantity allows researchers to validate their experimental approach and confirm compatibility with their assay system before committing to larger quantities. It minimises material investment in the early stages of a research project.

  • AOD-9604 10mg is the preferred format for established research programmes with higher throughput requirements, dose-response studies, multi-arm experiments comparing several concentration levels, or extended research programmes requiring multiple experimental runs. The 10mg format offers better value per milligram for programmes with confirmed demand.

No Certificate of Analysis is currently published for either format, so purity and identity are not documented for current stock. Both are dispatched under the same working-day UK dispatch standard, and the compound is the same in both quantities.

Sourcing AOD-9604 5mg in the UK: Quality Standards

The quality of AOD-9604 5mg directly determines the reliability and reproducibility of your experimental results. When evaluating potential suppliers as your AOD-9604 supplier UK, the following standards should be treated as non-negotiable:

  • HPLC purity verification: Purity should be measured by High-Performance Liquid Chromatography and stated on a batch-specific Certificate of Analysis (CoA). There is no single legal purity standard for research peptides, so compare the figure with your own study requirements.

  • Mass spectrometry identity confirmation: Molecular weight must be verified via LC-MS to confirm the 16-amino acid sequence and the intramolecular disulfide bond, both critical structural features of this compound.

  • Disulphide bond integrity: Particularly important for this compound, the disulphide bond between Cys-7 and Cys-14 must be correctly formed. Suppliers should confirm this through an appropriate analytical methodology.

  • Lyophilised format: Research peptides are usually supplied as freeze-dried powder; storage conditions should come from the manufacturer specification for the product.

  • Batch traceability: Full batch documentation, synthesis parameters, purification chromatograms, and QC release data must be maintained and available for institutional procurement compliance.

  • Research-only labelling: All products must carry unambiguous research-use-only designations with no therapeutic, clinical, or health-related claims.

  • UK-based dispatch: Sourcing from a UK-based peptide distributor minimises transit time and cold chain risk during shipping.

Ascend Peptides UK supplies AOD-9604 5mg as part of our comprehensive range of research peptides. No Janoshik certificate is currently published for AOD-9604; in-stock orders placed before 3 pm Monday to Friday are dispatched the same working day.

AOD-9604 5mg research peptide from Ascend Peptides UK trusted UK supplier

Regulatory Compliance and Research Responsibility

AOD-9604 is classified as a research chemical in the United Kingdom. It is not a licensed medicine, is not approved for human consumption, and must not be used in any clinical, therapeutic, diagnostic, or veterinary context. The fact that this compound is derived from a fragment of human GH does not confer any clinical or therapeutic status in the UK.

All purchasing researchers and institutions are fully responsible for ensuring their acquisition and use of this compound complies with applicable UK legislation and any relevant institutional ethics or procurement requirements. Ascend Peptides UK provides fully compliant, research-only labelled products and makes no health, clinical, metabolic, or performance-related claims about any compound in our range.

Conclusion: AOD-9604 5mg as a Metabolic Research Tool

AOD-9604 5mg occupies a unique and scientifically interesting position in the peptide research landscape. As a fragment of human Growth Hormone residues 177–191 with an added N-terminal tyrosine, this compound provides researchers with a focused tool for investigating the metabolic arm of GH signalling independently of the growth-promoting and IGF-1-stimulating effects associated with the full GH molecule.

Its documented research areas are lipolysis in obese rodent models, β3-AR expression as an indirect readout, and a single rabbit cartilage study. Human trials reported safety and no change in IGF-1, but the peer-reviewed summary does not report weight-loss efficacy. The 5mg format makes it particularly accessible for pilot studies, method development, and programmes at the early stages of incorporating this GH fragment into their experimental design.

For UK laboratories and research institutions seeking a reliable source of AOD-9604 5mg, Ascend Peptides UK supplies this compound for laboratory research with same working-day UK dispatch on in-stock orders; no Janoshik certificate is currently published for AOD-9604. Our team is ready to support your metabolic research programme.

Frequently Asked Questions About AOD-9604 5mg Research Peptide

Q: What is AOD-9604 5mg used for in research?
A: AOD-9604 5mg is used in laboratory research to investigate adipose tissue biology, lipid metabolism pathways, beta-3 adrenergic receptor expression, energy expenditure and, in one rabbit study, cartilage degeneration. As a synthetic peptide based on human GH residues 177-191 (with an added N-terminal tyrosine), it allows researchers to study the metabolic arm of GH signalling independently of IGF-1 pathway activation. Supplied strictly for research use only.
Q: What does AOD-9604 stand for?
A: AOD-9604 stands for Anti-Obesity Drug 9604. The ‘Anti-Obesity Drug’ designation reflects the original research focus of the compound’s development at Monash University in Australia. The number 9604 is the laboratory identifier assigned during development. It is a synthetic fragment of human Growth Hormone consisting of residues 177-191 with an added N-terminal tyrosine (Tyr-hGH(177-191)).
Q: What is the difference between AOD-9604 5mg and 10mg?
A: The compound is chemically identical in both formats; the only difference is the quantity supplied. AOD-9604 5mg is suited to smaller-scale studies, pilot experiments, and first-time sourcing of this compound. AOD-9604 10mg is preferred for established programmes with higher throughput requirements, dose-response studies, or extended experimental timelines. No Certificate of Analysis is currently published for either format.
Q: How does AOD-9604 differ from full-length Growth Hormone?
A: AOD-9604 is a 16-amino acid peptide based on the GH C-terminus (residues 177-191 plus an N-terminal tyrosine), representing less than 10% of the full 191-amino acid GH molecule. Unlike full-length GH, it did not change serum IGF-1 in placebo-controlled human trials (Stier et al., 2013) and is not reported to act through the GH receptor. It has been studied mainly for lipolysis and beta-3 adrenergic receptor expression in adipose tissue from obese rodents.
Q: Has AOD-9604 been studied in humans?
A: Yes. Six randomised, placebo-controlled trials (phases I to IIb) were run during its development as an anti-obesity drug. The peer-reviewed summary reports a safety and tolerability profile similar to placebo, no change in serum IGF-1, no adverse effect on glucose tolerance and no anti-AOD-9604 antibodies (Stier et al., 2013). It does not report weight-loss efficacy, and AOD-9604 was not approved as a medicine. These trials do not verify any research-supply batch.
Q: Is AOD-9604 legal to buy in the UK?
A: AOD-9604 is legal to purchase in the United Kingdom as a research chemical for laboratory and scientific investigation. It is not classified as a controlled substance under UK law. It is not approved for human consumption, clinical use, or therapeutic application. All buyers are responsible for ensuring their use complies with applicable UK legislation and any relevant institutional requirements.
Q: How does AOD-9604 work in laboratory research models?
A: In laboratory research models, AOD-9604 has been studied for lipolytic activity in adipose tissue models. Published research reported increased beta-3 adrenergic receptor expression in treated obese mice but concluded that its lipolytic actions are not mediated directly through the beta-3 adrenergic receptor. Effects on specific lipolytic enzymes or adipogenic transcription factors were not reported in the sources reviewed for this guide, and no specific receptor has been identified.
Q: What purity level is required for research-grade AOD-9604?
A: There is no single legal purity standard for research-grade AOD-9604; look for an HPLC (High-Performance Liquid Chromatography) purity figure on a batch-specific certificate and compare it with your study requirements. The 16-amino acid sequence and intramolecular disulfide bond must be verified by LC-MS. A batch-specific Certificate of Analysis documenting purity, identity, and QC release data should be provided by any reputable peptide supplier in the UK.
Q: Where can I buy AOD-9604 5mg research peptide in the UK?
A: AOD-9604 5mg is available from Ascend Peptides UK at ascendpeptidesuk.com/products/aod-9604. No Janoshik certificate is currently published for AOD-9604; in-stock orders placed before 3 pm are dispatched the same working day. Both 5mg and 10mg formats are available. All products are supplied for laboratory research use only.

References

  1. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID 11146367
  2. Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID 11713213
  3. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. PMID 10950816 (studies AOD9401, hGH 177-191, not AOD-9604)
  4. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. doi:10.4021/jem157w
  5. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015;45(4):426-432. PMID 26275694

DISCLAIMER

All products supplied by Ascend Peptides UK are intended strictly for research purposes only. They are not intended for human consumption or for any therapeutic, diagnostic, or clinical use. None of the items offered are classified as medicinal products by the MHRA. It is the buyer’s responsibility to ensure all purchases comply with applicable laws and regulations. Ascend Peptides UK accepts no liability for misuse.